MedPath

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Phase 4
Completed
Conditions
Cardiovascular Diseases
Registration Number
NCT00153101
Lead Sponsor
Boehringer Ingelheim
Brief Summary

The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint.

Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
31546
Inclusion Criteria

Coronary Artery Disease: Previous Myocardial infarction(> 2 days prior to informed consent), or stable or previous unstable angina (> 30 days prior to informed consent) with documented multivessel coronary artery disease or a positive stress test, or multivessel Percutaneous Transluminal Coronary Angioplasty (> 30 days prior to informed consent), or previous multivessel Coronary Artery Bypass Grafting without angina (if surgery performed > 4 years prior to informed consent) or with recurrent angina after surgery.

Other High Risk:

  1. Peripheral Arterial Disease: Previous limb bypass surgery or angioplasty or amputation, intermittent claudication on history with ankle/arm Blood Pressure ratio < 0.8 on at least one side, or significant stenosis by angiography or non-invasive testing
  2. Previous stroke
  3. Transient ischemic Attack > 7 days and < 1 year prior to informed consent
  4. Diabetes Mellitus (types I or II): with evidence of end-organ damage (retinopathy, Left ventricular hypertrophy, micro or macro albuminuria), or any evidence of previous cardiac or vascular disease.

No definite and specific indication or contraindication for any of the study treatments. Written informed consent.

Exclusion Criteria

A. Medication use:

  1. Inability to discontinue Angiotension Converting Enzyme (ACE) inhibitors or Angiotension 2 receptor antagonists (AIIAs).
  2. Patients with known hypersensitivity or intolerance to Angiotension 2 receptor antagonists (AIIAs) or Angiotension Converting Enzyme (ACE)inhibitors.

NOTE: Patients with known intolerance to Angiotension Converting Enzyme inhibitor intolerance ( ACE-I) can be enrolled in the TRANSCEND study.

B. Cardiovascular disease:

  1. Symptomatic congestive heart failure.
  2. Hemodynamically significant primary valvular or outflow tract obstruction (e.g. aortic or mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve).
  3. Constrictive pericarditis.
  4. Complex congenital heart disease.
  5. Syncopal episodes of unknown etiology < 3 months before informed consent.
  6. Planned cardiac surgery or angioplasty within three months.
  7. Uncontrolled hypertension on treatment (i.e.Blood pressure ( BP) > 160/100).
  8. Heart transplant recipient.
  9. Strokes due to subarachnoid hemorrhage

C. Other conditions:

  1. Significant renal disease defined as:

    1. Renal artery stenosis;
    2. Creatinine clearance < 0.6 ml/min or serum creatinine > 265 umol/L (> 3.0 mg/dL);
    3. Hyperkalemia: potassium > 5.5 mmol/L.
    4. Proteinuria* (for TRANSCEND only).

  2. Hepatic dysfunction as defined by the following laboratory parameters: Serum Glutamate Pyruvate Transaminase( SGPT) Alaninaminotransferase (ALT) or Serum Glutamic Oxaloacetic Transaminase (SGOT) Aspartate aminotransferase (AST) > than 4 times upper limit of normal or additional criteria for hepatic impairment the upper limit of normal range, total Bilirubin > 20 umol/L, biliary obstructive disorders.

  3. Uncorrected volume depletion or sodium depletion.

  4. Primary aldosteronism.

  5. Hereditary fructose intolerance.

  6. Any other major non-cardiac illness expected to reduce life expectancy or interfere with study participation.

  7. Patient is simultaneously taking another experimental drug.

  8. Patient with significant disability that precludes regular attendance at clinic for follow-up.

  9. Patient has sufficient disability or other incapacity that precludes regular attendance at clinic for follow-up.

  10. Unable or unwilling to provide written informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure56 months

Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.

ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients56 months

ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR \<15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.

These renal outcomes were not adjudicated (apart from death).

ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure56 months

The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.

Secondary Outcome Measures
NameTimeMethod
TRANSCEND. New Onset of Atrial Fibrillation56 months

Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).

ONTARGET. All-cause Mortality in Diabetic Nephropathy Patients56 months

Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.

ONTARGET. New Microalbuminuria56 months

ONTARGET. Nephropathy subcategory: New microalbuminuria. New microalbuminuria is defined as Urinary Albumin Creatinine Ratio ≥30 mg/g Crea in patients with a Urinary Albumin Creatinine Ratio \<30 mg/g Crea at baseline.

ONTARGET. Newly Diagnosed Diabetes56 months

The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint Newly diagnosed Diabetes. Only calculated for those patients without diabetes at baseline.

ONTARGET. Cardiovascular Death56 months

The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint cardiovascular death.

ONTARGET. Non-fatal Myocardial Infarction56 months

The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint non-fatal myocardial infarction.

ONTARGET. Hospitalization for Congestive Heart Failure56 months

The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint hospitalization for congestive heart failure.

ONTARGET. Doubling of Serum Creatinine56 months

ONTARGET. Nephropathy subcategory: doubling of serum creatinine

ONTARGET. Newly Diagnosed Congestive Heart Failure56 months

The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint Newly diagnosed Congestive Heart failure.

ONTARGET. Cardiovascular Revascularization Procedure56 months

The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).

ONTARGET. Cognitive Decline56 months

The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the endpoint cognitive decline i.e. Comparison of the Mini mental state Evaluation (MMSE) of patients at baseline with that at the 2years and end of trial. A decrease in MMSE from baseline represents a cognitive decline. This outcome measure is only available for those patients who had MMSE at baseline.

TRANSCEND. Cognitive Decline56 months

Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the endpoint cognitive decline i.e. Comparison of the Mini mental state Evaluation (MMSE) of patients at baseline with that at the 2years and end of trial. A decrease in MMSE from baseline represents a cognitive decline. This outcome measure is only available for those patients who had MMSE at baseline.

TRANSCEND. Cardiovascular Revascularization Procedure56 months

Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).

ONTARGET. Doubling of Serum Creatinine in Diabetic Nephropathy Patients56 months

Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.

ONTARGET. Progression to ESRD56 months

ONTARGET. Nephropathy subcategory: Progression to ESRD. Progression to ESRD is defined as initiation of dialysis, need for renal transplantation, or eGFR \<15 mL/min/1.73 m².

ONTARGET. Combined Endpoint of Doubling of Serum Creatinine, Progression to ESRD, New Microalbuminuria, or New Macroalbuminuria56 months

ONTARGET. Nephropathy subcategory: Combined endpoint of doubling of serum creatinine, progression to ESRD, new microalbuminuria, or new macroalbuminuria

ONTARGET. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria56 months

ONTARGET. Nephropathy subcategory: Normalisation from micro- or macroalbuminuria to normoalbuminuria. Normalisation from micro- or macroalbuminuria to normoalbuminuria is defined as UACR \<30 mg/g Crea in patients with a UACR ≥30 mg/g Crea at baseline.

TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke56 months

Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.

TRANSCEND. Hospitalization for Congestive Heart Failure56 months

Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).

TRANSCEND. Progression to ESRD56 months

TRANSCEND. Nephropathy subcategory: Progression to ESRD. Progression to ESRD is defined as initiation of dialysis, need for renal transplantation, or eGFR \<15 mL/min/1.73m²

TRANSCEND. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria56 months

TRANSCEND. Nephropathy subcategory: Normalisation from micro- or macroalbuminuria to normoalbuminuria. Normalisation from micro- or macroalbuminuria to normoalbuminuria is defined as UACR \<30 mg/g Crea in patients with a UACR ≥30 mg/g Crea at baseline.

TRANSCEND. Newly Diagnosed Diabetes56 months

Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint Newly diagnosed Diabetes. Only calculated for those patients without diabetes at baseline.

ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke56 months

The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, non-fatal myocardial infarction or non-fatal stroke

ONTARGET. Non-fatal Stroke56 months

The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the endpoint non-fatal stroke.

ONTARGET. Progression to End Stage Renal Disease (ESRD) in Diabetic Nephropathy Patients56 months

ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR \<15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.

ONTARGET. New Onset of Atrial Fibrillation56 months

The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of endpoint new onset of atrial fibrillation.

TRANSCEND. New Microalbuminuria56 months

TRANSCEND. Nephropathy subcategory: New microalbuminuria. New microalbuminuria is defined as UACR ≥30 mg/g creatinine \[Crea\] in patients with a UACR \<30 mg/g Crea at baseline

ONTARGET. New Macroalbuminuria56 months

ONTARGET. Nephropathy subcategory: New macroalbuminuria. New macroalbuminuria is defined as Urinary Albumin Creatinine Ratio ≥300 mg/g Crea in patients with a Urinary Albumin Creatinine Ratio \<300 mg/g Crea at baseline.

TRANSCEND. Cardiovascular Death56 months

Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint cardiovascular death.

TRANSCEND. Non-fatal Stroke56 months

Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).

TRANSCEND. Combined Endpoint of Doubling Serum Creatinine, Progression to ESRD, New Microalbuminuria or New Macroalbuminuria56 months

TRANSCEND. Nephropathy subcategory: Combined endpoint of doubling serum creatinine, progression to ESRD, new microalbuminuria or new macroalbuminuria

TRANSCEND. Newly Diagnosed Congestive Heart Failure56 months

Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).

TRANSCEND. Non-fatal Myocardial Infarction56 months

Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint non-fatal myocardial infarction.

TRANSCEND. Doubling of Serum Creatinine56 months

TRANSCEND. Nephropathy subcategory: doubling of serum creatinine

TRANSCEND. New Macroalbuminuria56 months

TRANSCEND. Nephropathy subcategory: New macroalbuminuria. New macroalbuminuria is defined as UACR ≥300 mg/g creatinine \[Crea\] in patients with a UACR \<300 mg/g Crea at baseline

Trial Locations

Locations (732)

502.373.0247 Boehringer Ingelheim Investigational Site

🇺🇸

Baltimore, Maryland, United States

502.373.0177 Boehringer Ingelheim Investigational Site

🇺🇸

Tuscon, Arizona, United States

502.373.0529 Launceston General Hospital

🇦🇺

Launceston, Tasmania, Australia

502.373.0033 Clinique de Cardiologie de Levis

🇨🇦

Levis, Quebec, Canada

502.373.0072 Chra

🇨🇦

Thetford Mines, Quebec, Canada

502.373.0053 Mount Royal Clinic

🇨🇦

Saskatoon, Saskatchewan, Canada

502.373.0013 Suite 170

🇨🇦

Longueuil, Quebec, Canada

502.373.0025 Hopital Maisonneuve Rosemont

🇨🇦

Montreal, Quebec, Canada

502.373.0079 Jewish General Hospital

🇨🇦

Montreal, Quebec, Canada

502.373.0021 Medi - recherche Inc.

🇨🇦

Montreal, Quebec, Canada

502.373.0067 SDRI - University of Saskatchewan

🇨🇦

Saskatoon, Saskatchewan, Canada

502.373.0055 Specialists - Internal Medicine

🇨🇦

Saskatoon, Saskatchewan, Canada

502.373.0068 SDRI - University of Saskatchewan

🇨🇦

Saskatoon, Saskatchewan, Canada

502.373.1471 Boehringer Ingelheim Investigational Site

🇫🇮

Turku, Finland

502.373.0702 De La Salle University Medical Center

🇵🇭

Cavite, Philippines

502.373.0700 Philippine General Hospital

🇵🇭

Manila, Philippines

502.373.0701 Manila Doctors Hospital, Room 3 Annex

🇵🇭

Manila, Philippines

502.373.0267 Boehringer Ingelheim Investigational Site

🇵🇷

Las Lomas, Puerto Rico

502.373.0190 Boehringer Ingelheim Investigational Site

🇵🇷

Manati, Puerto Rico

502.373.0524 Royal Brisbane Hospital

🇦🇺

Herston, Queensland, Australia

502.373.0256 Boehringer Ingelheim Investigational Site

🇺🇸

Athens, Alabama, United States

502.373.0226 Boehringer Ingelheim Investigational Site

🇺🇸

Bridgeport, Connecticut, United States

502.373.0083 St. Michael's Hospital

🇨🇦

Toronto, Ontario, Canada

502.373.0015 C/O Peter Carmichael

🇨🇦

Longueuil, Quebec, Canada

502.373.0017 Suite 170

🇨🇦

Longueuil, Quebec, Canada

502.373.0187 Boehringer Ingelheim Investigational Site

🇺🇸

Dallas, Texas, United States

502.373.0031 Brampton Research Associates

🇨🇦

Brampton, Ontario, Canada

502.373.0058 Medical Sciences Building

🇨🇦

Oshawa, Ontario, Canada

502.373.0014 Via Car Recherche Clinique Inc

🇨🇦

Longueuil, Quebec, Canada

502.373.0272 Boehringer Ingelheim Investigational Site

🇺🇸

Chicago, Illinois, United States

502.373.0164 Boehringer Ingelheim Investigational Site

🇺🇸

Cleveland, Ohio, United States

502.373.0761 Boehringer Ingelheim Investigational Site

🇰🇷

Seoul, Korea, Republic of

502.373.0736 Boehringer Ingelheim Investigational Site

🇲🇾

Johor Baharu, Malaysia

502.373.0739 Boehringer Ingelheim Investigational Site

🇲🇾

Kelantan, Malaysia

502.373.1302 Boehringer Ingelheim Investigational Site

🇳🇱

Doetinchem, Netherlands

502.373.1304 Boehringer Ingelheim Investigational Site

🇳🇱

Drachten, Netherlands

502.373.0705 The Medical City

🇵🇭

Pasig City, Philippines

502.373.1366 Boehringer Ingelheim Investigational Site

🇵🇱

Czestochowa, Poland

502.373.1360 Boehringer Ingelheim Investigational Site

🇵🇱

Jaroslawiec, Poland

502.373.1370 Boehringer Ingelheim Investigational Site

🇵🇱

Poznan, Poland

502.373.1355 Boehringer Ingelheim Investigational Site

🇵🇱

Tomaszow Mazowiecki, Poland

502.373.1560 Boehringer Ingelheim Investigational Site

🇿🇦

Fiachrdtpark, Bloemfontein, South Africa

502.373.1555 Boehringer Ingelheim Investigational Site

🇿🇦

Park Town West, South Africa

502.373.1590 Boehringer Ingelheim Investigational Site

🇪🇸

Barcelona, Spain

502.373.1601 Boehringer Ingelheim Investigational Site

🇪🇸

Alicante, Spain

502.373.1577 Boehringer Ingelheim Investigational Site

🇪🇸

Málaga, Spain

502.373.1505 Jakobsbergs sjukhus

🇸🇪

Järfälla, Sweden

502.373.1639 Boehringer Ingelheim Investigational Site

🇨🇭

Lausanne, Switzerland

502.373.0217 Boehringer Ingelheim Investigational Site

🇺🇸

Olympia Fields, Illinois, United States

502.373.0244 Boehringer Ingelheim Investigational Site

🇺🇸

Burbank, Illinois, United States

502.373.0229 Boehringer Ingelheim Investigational Site

🇺🇸

Springfield, Massachusetts, United States

502.373.0284 Boehringer Ingelheim Investigational Site

🇺🇸

Boston, Massachusetts, United States

502.373.0803 Boehringer Ingelheim Investigational Site

🇹🇭

Khon Kaen, Thailand

502.373.0057 Centre De Recherche Clinique

🇨🇦

Laval, Quebec, Canada

502.373.0605 Boehringer Ingelheim Investigational Site

🇨🇳

Beijing, China

502.373.0612 Boehringer Ingelheim Investigational Site

🇨🇳

Harbin, China

502.373.0610 Boehringer Ingelheim Investigational Site

🇨🇳

Zhenzhou, China

502.373.1051 Boehringer Ingelheim Investigational Site

🇨🇿

Prague 5, Czech Republic

502.373.1057 Boehringer Ingelheim Investigational Site

🇨🇿

Prague, Czech Republic

502.373.1062 Boehringer Ingelheim Investigational Site

🇨🇿

Praha 2, Czech Republic

502.373.1481 Boehringer Ingelheim Investigational Site

🇫🇮

Kuusankoski, Finland

502.373.1097 Cabinet Médical

🇫🇷

Castelnaudary, France

502.373.1091 Cabinet Médical

🇫🇷

Broglie, France

502.373.1150 Boehringer Ingelheim Investigational Site

🇩🇪

Sindelfingen, Germany

502.373.1140 Boehringer Ingelheim Investigational Site

🇩🇪

Rostock, Germany

502.373.1158 Boehringer Ingelheim Investigational Site

🇩🇪

Stuttgart, Germany

502.373.1167 Boehringer Ingelheim Investigational Site

🇩🇪

Timmendorfer Strand, Germany

502.373.1210 Boehringer Ingelheim Investigational Site

🇬🇷

Kavala,greece, Greece

502.373.1213 Boehringer Ingelheim Investigational Site

🇬🇷

Thessaloniki, Greece

502.373.1224 Boehringer Ingelheim Investigational Site

🇬🇷

Korinthos, Greece

502.373.1205 Boehringer Ingelheim Investigational Site

🇬🇷

Thessaloniki, Greece

502.373.1227 Boehringer Ingelheim Investigational Site

🇭🇺

Budapest, Hungary

502.373.0280 Boehringer Ingelheim Investigational Site

🇺🇸

Houston, Texas, United States

502.373.0281 Boehringer Ingelheim Investigational Site

🇺🇸

Seattle, Washington, United States

502.373.0165 Boehringer Ingelheim Investigational Site

🇺🇸

San Diego, California, United States

502.373.0155 Boehringer Ingelheim Investigational Site

🇺🇸

Cincinnati, Ohio, United States

502.373.358 Boehringer Ingelheim Investigational Site

🇦🇷

Córdoba, Argentina

502.373.0228 Boehringer Ingelheim Investigational Site

🇺🇸

San Leandro, California, United States

502.373.0208 Boehringer Ingelheim Investigational Site

🇺🇸

Minneapolis, Minnesota, United States

502.373.0232 Boehringer Ingelheim Investigational Site

🇺🇸

Minneapolis, Minnesota, United States

502.373.1261 Ospedale Civile di Casarano

🇮🇹

Casarano (LE), Italy

502.373.0779 Boehringer Ingelheim Investigational Site

🇨🇳

Chia-Yi, Taiwan

502.373.0222 Boehringer Ingelheim Investigational Site

🇺🇸

Fargo, North Dakota, United States

502.373.0530 Sir Charles Gairdner Hospital

🇦🇺

Nedlands, Western Australia, Australia

502.373.0545 Royal Perth Hospital

🇦🇺

Perth, Western Australia, Australia

502.373.0547 Fremantle Hospital

🇦🇺

Fremantle, Western Australia, Australia

502.373.0050 St. Pierre Medical Clinic

🇨🇦

St. Pierre, Manitoba, Canada

502.373.1455 Boehringer Ingelheim Investigational Site

🇩🇰

Frederiksberg, Denmark

502.373.1458 Boehringer Ingelheim Investigational Site

🇩🇰

Hilleroed, Denmark

502.373.1086 Cabinet Médical

🇫🇷

Nantes, France

502.373.0023 Group Health Centre - Clinical Trials

🇨🇦

Sault Ste Marie, Ontario, Canada

502.373.0251 Boehringer Ingelheim Investigational Site

🇺🇸

Birmingham, Alabama, United States

502.373.0182 Boehringer Ingelheim Investigational Site

🇺🇸

Phoenix, Arizona, United States

502.373.0188 Boehringer Ingelheim Investigational Site

🇺🇸

Phoenix, Arizona, United States

502.373.0279 Boehringer Ingelheim Investigational Site

🇺🇸

Omaha, Nebraska, United States

502.373.0154 Boehringer Ingelheim Investigational Site

🇺🇸

Oklahoma City, Oklahoma, United States

502.373.0243 Boehringer Ingelheim Investigational Site

🇺🇸

Portland, Oregon, United States

502.373.0212 Boehringer Ingelheim Investigational Site

🇺🇸

Milwaukee, Wisconsin, United States

502.373.0171 Boehringer Ingelheim Investigational Site

🇺🇸

Tampa, Florida, United States

502.373.0209 Boehringer Ingelheim Investigational Site

🇺🇸

Bentonville, Arkansas, United States

502.373.0189 Boehringer Ingelheim Investigational Site

🇺🇸

Tucson, Arizona, United States

502.373.0173 Boehringer Ingelheim Investigational Site

🇺🇸

Concord, California, United States

502.373.0283 Boehringer Ingelheim Investigational Site

🇺🇸

Loma Linda, California, United States

502.373.0266 Boehringer Ingelheim Investigational Site

🇺🇸

Harbor City, California, United States

502.373.0180 Boehringer Ingelheim Investigational Site

🇺🇸

Los Angeles, California, United States

502.373.0277 Boehringer Ingelheim Investigational Site

🇺🇸

West Hills, California, United States

502.373.0205 Boehringer Ingelheim Investigational Site

🇺🇸

Sylmar, California, United States

502.373.0240 Boehringer Ingelheim Investigational Site

🇺🇸

Panama City, Florida, United States

502.373.0174 Boehringer Ingelheim Investigational Site

🇺🇸

Farmington, Connecticut, United States

502.373.0183 Boehringer Ingelheim Investigational Site

🇺🇸

Palm Harbor, Florida, United States

502.373.0258 Boehringer Ingelheim Investigational Site

🇺🇸

Washington, District of Columbia, United States

502.373.0282 Boehringer Ingelheim Investigational Site

🇺🇸

Vero Beach, Florida, United States

502.373.0214 Boehringer Ingelheim Investigational Site

🇺🇸

Weston, Florida, United States

502.373.0201 Boehringer Ingelheim Investigational Site

🇺🇸

Augusta, Georgia, United States

502.373.0223 Boehringer Ingelheim Investigational Site

🇺🇸

Conyers, Georgia, United States

502.373.0199 Boehringer Ingelheim Investigational Site

🇺🇸

Tucker, Georgia, United States

502.373.0162 Boehringer Ingelheim Investigational Site

🇺🇸

Valdosta, Georgia, United States

502.373.0268 Boehringer Ingelheim Investigational Site

🇺🇸

Sandersville, Georgia, United States

502.373.0203 Boehringer Ingelheim Investigational Site

🇺🇸

Pocatello, Idaho, United States

502.373.0167 Boehringer Ingelheim Investigational Site

🇺🇸

Monroe, Louisiana, United States

502.373.0231 Boehringer Ingelheim Investigational Site

🇺🇸

St. Paul, Minnesota, United States

502.373.0237 Boehringer Ingelheim Investigational Site

🇺🇸

Wyandotte, Michigan, United States

502.373.0181 Boehringer Ingelheim Investigational Site

🇺🇸

Biloxi, Mississippi, United States

502.373.0169 Boehringer Ingelheim Investigational Site

🇺🇸

North Las Vegas, Nevada, United States

502.373.0207 Boehringer Ingelheim Investigational Site

🇺🇸

St. Louis, Missouri, United States

502.373.0185 Boehringer Ingelheim Investigational Site

🇺🇸

Cleveland, Mississippi, United States

502.373.0254 Boehringer Ingelheim Investigational Site

🇺🇸

Jackson, Mississippi, United States

502.373.0202 Boehringer Ingelheim Investigational Site

🇺🇸

East Orange, New Jersey, United States

502.373.0157 Boehringer Ingelheim Investigational Site

🇺🇸

Camden, New Jersey, United States

502.373.0191 Boehringer Ingelheim Investigational Site

🇺🇸

Newark, New Jersey, United States

502.373.0271 Boehringer Ingelheim Investigational Site

🇺🇸

Westwood, New Jersey, United States

502.373.0213 Boehringer Ingelheim Investigational Site

🇺🇸

Brooklyn, New York, United States

502.373.0230 Boehringer Ingelheim Investigational Site

🇺🇸

Buffalo, New York, United States

502.373.0288 Boehringer Ingelheim Investigational Site

🇺🇸

Kingston, New York, United States

502.373.0238 Boehringer Ingelheim Investigational Site

🇺🇸

New York, New York, United States

502.373.0252 Boehringer Ingelheim Investigational Site

🇺🇸

New York, New York, United States

502.373.0227 Boehringer Ingelheim Investigational Site

🇺🇸

Scarsdale, New York, United States

502.373.0286 Boehringer Ingelheim Investigational Site

🇺🇸

New York, New York, United States

502.373.0163 Boehringer Ingelheim Investigational Site

🇺🇸

Westfield, New York, United States

502.373.0273 Boehringer Ingelheim Investigational Site

🇺🇸

Durham, North Carolina, United States

502.373.0166 Boehringer Ingelheim Investigational Site

🇺🇸

Northport, New York, United States

502.373.0241 Boehringer Ingelheim Investigational Site

🇺🇸

Williamsville, New York, United States

502.373.0261 Boehringer Ingelheim Investigational Site

🇺🇸

Winston Salem, North Carolina, United States

502.373.0178 Boehringer Ingelheim Investigational Site

🇺🇸

Oklahoma City, Ohio, United States

502.373.0259 Boehringer Ingelheim Investigational Site

🇺🇸

Guthrie, Oklahoma, United States

502.373.0159 Boehringer Ingelheim Investigational Site

🇺🇸

Mansfield, Ohio, United States

502.373.0152 Boehringer Ingelheim Investigational Site

🇺🇸

Tulsa, Oklahoma, United States

502.373.0153 Boehringer Ingelheim Investigational Site

🇺🇸

Philadelphia, Pennsylvania, United States

502.373.0265 Boehringer Ingelheim Investigational Site

🇺🇸

Erie, Pennsylvania, United States

502.373.0274 Boehringer Ingelheim Investigational Site

🇺🇸

Sellersville, Pennsylvania, United States

502.373.0248 Boehringer Ingelheim Investigational Site

🇺🇸

Columbia, South Carolina, United States

502.373.0172 Boehringer Ingelheim Investigational Site

🇺🇸

Dallas, Texas, United States

502.373.0275 Boehringer Ingelheim Investigational Site

🇺🇸

Dallas, Texas, United States

502.373.0206 Boehringer Ingelheim Investigational Site

🇺🇸

Houston, Texas, United States

502.373.0219 Boehringer Ingelheim Investigational Site

🇺🇸

Dallas, Texas, United States

502.373.0249 Boehringer Ingelheim Investigational Site

🇺🇸

Burke, Virginia, United States

502.373.0234 Boehringer Ingelheim Investigational Site

🇺🇸

Houston, Texas, United States

502.373.353 Boehringer Ingelheim Investigational Site

🇦🇷

Capital Federal, Argentina

502.373.351 Boehringer Ingelheim Investigational Site

🇦🇷

Capital Federal, Argentina

502.373.350 Boehringer Ingelheim Investigational Site

🇦🇷

Capital Federal, Argentina

502.373.352 Boehringer Ingelheim Investigational Site

🇦🇷

Capital Federal, Argentina

502.373.354 Boehringer Ingelheim Investigational Site

🇦🇷

Capital Federal, Argentina

502.373.356 Boehringer Ingelheim Investigational Site

🇦🇷

Capital Federal, Argentina

502.373.378 Boehringer Ingelheim Investigational Site

🇦🇷

Capital Federal, Argentina

502.373.355 Boehringer Ingelheim Investigational Site

🇦🇷

Capital Federal, Argentina

502.373.362 Boehringer Ingelheim Investigational Site

🇦🇷

Corones Suárez, Argentina

502.373.357 Boehringer Ingelheim Investigational Site

🇦🇷

Córdoba, Argentina

502.373.360 Boehringer Ingelheim Investigational Site

🇦🇷

Córdoba, Argentina

502.373.361 Boehringer Ingelheim Investigational Site

🇦🇷

Córdoba, Argentina

502.373.364 Boehringer Ingelheim Investigational Site

🇦🇷

La Plata, Argentina

502.373.365 Boehringer Ingelheim Investigational Site

🇦🇷

Mar del Plata, Argentina

502.373.377 Boehringer Ingelheim Investigational Site

🇦🇷

Córdoba, Argentina

502.373.366 Boehringer Ingelheim Investigational Site

🇦🇷

Mendoza, Argentina

502.373.376 Boehringer Ingelheim Investigational Site

🇦🇷

Mendoza, Argentina

502.373.367 Boehringer Ingelheim Investigational Site

🇦🇷

Rosario, Argentina

502.373.375 Boehringer Ingelheim Investigational Site

🇦🇷

Santa Fe, Argentina

502.373.369 Boehringer Ingelheim Investigational Site

🇦🇷

Salta, Argentina

502.373.371 Boehringer Ingelheim Investigational Site

🇦🇷

Tucumán, Argentina

502.373.373 Boehringer Ingelheim Investigational Site

🇦🇷

Tucumán, Argentina

502.373.374 Boehringer Ingelheim Investigational Site

🇦🇷

Zárate, Argentina

502.373.0534 The Canberra Hospital

🇦🇺

Woden, Australian Capital Territory, Australia

502.373.0536 Royal Prince Alfred Hospital

🇦🇺

Camperdown, New South Wales, Australia

502.373.0538 Concord Repatriation General Hospital

🇦🇺

Concord, New South Wales, Australia

502.373.0544 Coffs Harbour Cardiovascular Clinic

🇦🇺

Coffs Harbour, New South Wales, Australia

502.373.0542 St. George Hospital

🇦🇺

Kogarah, New South Wales, Australia

502.373.0539 Central Coast Neuroscience Research

🇦🇺

Gosford, New South Wales, Australia

502.373.0556 Gosford Hospital

🇦🇺

Gosford, New South Wales, Australia

502.373.0552 St George Private Hospital

🇦🇺

Kogarah, New South Wales, Australia

502.373.0559 St George Hospital - Dept of Clinical Pharmacology

🇦🇺

Kogarah, New South Wales, Australia

502.373.0528 John Hunter Hospital

🇦🇺

Newcastle, New South Wales, Australia

502.373.0535 The Prince of Wales Hospital

🇦🇺

Randwick, New South Wales, Australia

502.373.0533 Royal North Shore Hospital

🇦🇺

St Leonards, New South Wales, Australia

502.373.0526 Peninsula Clinical Research Centre

🇦🇺

Kippa-Ring, Queensland, Australia

502.373.0549 Illawarra Regional Hospital

🇦🇺

Wollongong, New South Wales, Australia

502.373.0523 The Prince Charles Hospital

🇦🇺

Chermside, Queensland, Australia

502.373.0540 Gold Coast Hospital

🇦🇺

Southport, Queensland, Australia

502.373.0521 Princess Alexandra Hospital

🇦🇺

Woolloongabba, Queensland, Australia

502.373.0546 Flinders Medical Centre

🇦🇺

Bedford Park, South Australia, Australia

502.373.0551 Port Lincoln "The Investigator" Clinic

🇦🇺

Port Lincoln, South Australia, Australia

502.373.0550 Repatriation General Hospital

🇦🇺

Daw Park, South Australia, Australia

502.373.0531 Box Hill Hospital

🇦🇺

Box Hill, Victoria, Australia

502.373.0548 The Northern Hospital

🇦🇺

Epping, Victoria, Australia

502.373.0525 The Alfred Hospital

🇦🇺

Prahran, Victoria, Australia

502.373.0520 Royal Melbourne Hospital

🇦🇺

Parkville, Victoria, Australia

502.373.0522 The Geelong Hospital

🇦🇺

Geelong, Victoria, Australia

502.373.0537 Austin & Repatriation Medical Centre

🇦🇺

West Heidelberg, Victoria, Australia

502.373.0532 Baker Medical Research Centre

🇦🇺

Prahran, Victoria, Australia

502.373.0557 Maroondah Hospital

🇦🇺

Ringwood East, Victoria, Australia

502.373.1125 Boehringer Ingelheim Investigational Site

🇦🇹

Wels, Austria

502.373.1126 Boehringer Ingelheim Investigational Site

🇦🇹

Wien, Austria

502.373.1128 Boehringer Ingelheim Investigational Site

🇦🇹

Graz, Austria

502.373.1127 Boehringer Ingelheim Investigational Site

🇦🇹

Wien, Austria

502.373.1129 Boehringer Ingelheim Investigational Site

🇦🇹

Wien, Austria

502.373.1004 Boehringer Ingelheim Investigational Site

🇧🇪

Aalst, Belgium

502.373.1015 Boehringer Ingelheim Investigational Site

🇧🇪

Anderlecht, Belgium

502.373.1005 Boehringer Ingelheim Investigational Site

🇧🇪

Antwerpen, Belgium

502.373.1022 Boehringer Ingelheim Investigational Site

🇧🇪

Bornem, Belgium

502.373.1003 Boehringer Ingelheim Investigational Site

🇧🇪

Brugge, Belgium

502.373.1021 Boehringer Ingelheim Investigational Site

🇧🇪

Brasschaat, Belgium

502.373.1009 Boehringer Ingelheim Investigational Site

🇧🇪

Genk, Belgium

502.373.1018 Boehringer Ingelheim Investigational Site

🇧🇪

Godinne, Belgium

502.373.1017 Boehringer Ingelheim Investigational Site

🇧🇪

Charleroi, Belgium

502.373.1011 Boehringer Ingelheim Investigational Site

🇧🇪

Haine-Saint-Paul, Belgium

502.373.1007 Boehringer Ingelheim Investigational Site

🇧🇪

Hasselt, Belgium

502.373.1000 Boehringer Ingelheim Investigational Site

🇧🇪

Leuven, Belgium

502.373.1019 Boehringer Ingelheim Investigational Site

🇧🇪

Haine-Saint-Paul, Belgium

502.373.1028 Boehringer Ingelheim Investigational Site

🇧🇪

Roeselare, Belgium

502.373.1014 Boehringer Ingelheim Investigational Site

🇧🇪

Seraing, Belgium

502.373.1020 Boehringer Ingelheim Investigational Site

🇧🇪

Mechelen, Belgium

502.373.1006 Boehringer Ingelheim Investigational Site

🇧🇪

Mol, Belgium

502.373.1010 Boehringer Ingelheim Investigational Site

🇧🇪

Turnhout, Belgium

502.373.1025 Boehringer Ingelheim Investigational Site

🇧🇪

Woluwé-Saint-Lambert, Belgium

502.373.1002 Boehringer Ingelheim Investigational Site

🇧🇪

Turnhout, Belgium

502.373.405 Boehringer Ingelheim Investigational Site

🇧🇷

Belo Horizonte, Brazil

502.373.412 Boehringer Ingelheim Investigational Site

🇧🇷

Belo Horizonte, Brazil

502.373.426 Boehringer Ingelheim Investigational Site

🇧🇷

Belo Horizonte, Brazil

502.373.407 Boehringer Ingelheim Investigational Site

🇧🇷

Campinas, Brazil

502.373.418 Boehringer Ingelheim Investigational Site

🇧🇷

Botucatu -, Brazil

502.373.419 Boehringer Ingelheim Investigational Site

🇧🇷

Campinas, Brazil

502.373.406 Boehringer Ingelheim Investigational Site

🇧🇷

Curitiba, Brazil

502.373.425 Boehringer Ingelheim Investigational Site

🇧🇷

Cerqueira César - São Paulo, Brazil

502.373.411 Boehringer Ingelheim Investigational Site

🇧🇷

Goiania, Brazil

502.373.403 Boehringer Ingelheim Investigational Site

🇧🇷

Marília, Brazil

502.373.400 Boehringer Ingelheim Investigational Site

🇧🇷

Pelotas, Brazil

502.373.415 Boehringer Ingelheim Investigational Site

🇧🇷

Porto Alegre - Rs, Brazil

502.373.416 Boehringer Ingelheim Investigational Site

🇧🇷

Porto Alegre, Brazil

502.373.420 Boehringer Ingelheim Investigational Site

🇧🇷

Ribeirao Preto, Brazil

502.373.417 Boehringer Ingelheim Investigational Site

🇧🇷

Porto Alegre, Brazil

502.373.421 Boehringer Ingelheim Investigational Site

🇧🇷

Sao Jose do Rio Preto, Brazil

502.373.413 Boehringer Ingelheim Investigational Site

🇧🇷

Rio de Janeiro - Rj, Brazil

502.373.409 Boehringer Ingelheim Investigational Site

🇧🇷

Salvador, Brazil

502.373.422 Boehringer Ingelheim Investigational Site

🇧🇷

Sao Paulo, Brazil

502.373.410 Boehringer Ingelheim Investigational Site

🇧🇷

Salvador, Brazil

502.373.404 Boehringer Ingelheim Investigational Site

🇧🇷

Santa Catalina, Brazil

502.373.414 Boehringer Ingelheim Investigational Site

🇧🇷

Rio de Janeiro, Brazil

502.373.424 Boehringer Ingelheim Investigational Site

🇧🇷

São Paulo, Brazil

502.373.402 Boehringer Ingelheim Investigational Site

🇧🇷

São Paulo, Brazil

502.373.408 Boehringer Ingelheim Investigational Site

🇧🇷

São Paulo, Brazil

502.373.0001 C849 Division of Cardiology, Foothills Medical Centre

🇨🇦

Calgary, Alberta, Canada

502.373.423 Boehringer Ingelheim Investigational Site

🇧🇷

Vila Clementino, São Paulo, Brazil

502.373.0071 Peter Lougheed Centre

🇨🇦

Calgary, Alberta, Canada

502.373.0062 Gain Medical Centre

🇨🇦

Coquitlam, British Columbia, Canada

502.373.0073 Alder Medical Centre

🇨🇦

Campbell river, British Columbia, Canada

502.373.0003 Discovery Clinical Services Ltd

🇨🇦

Victoria, British Columbia, Canada

502.373.0046 Interior Clinical Research Consultants Ltd

🇨🇦

Kelowna, British Columbia, Canada

502.373.0009 Vancouver Hospital

🇨🇦

Vancouver, British Columbia, Canada

502.373.0038 New West Cardiac Research

🇨🇦

New Westminster, British Columbia, Canada

502.373.0002 Penticton Regional Hospital

🇨🇦

Penticton, British Columbia, Canada

502.373.0048 Suite 100

🇨🇦

North Vancouver, British Columbia, Canada

502.373.0006 The General Hospital

🇨🇦

St. John's, Newfoundland and Labrador, Canada

502.373.0005 Dr. Jeffrey Hiscock

🇨🇦

ST John's, Newfoundland and Labrador, Canada

502.373.0056 Antigonish Clinical Trials

🇨🇦

Antigonish, Nova Scotia, Canada

502.373.0011 St. Joseph's Hospital Cardiac Research

🇨🇦

Hamilton, Ontario, Canada

502.373.0034 HGH McMaster Clinic

🇨🇦

Hamilton, Ontario, Canada

502.373.0035 Hamilton Medical Research

🇨🇦

Hamilton, Ontario, Canada

502.373.0064 Chedoke Hospital

🇨🇦

Hamilton, Ontario, Canada

502.373.0085 HGH McMaster Clinic

🇨🇦

Hamilton, Ontario, Canada

502.373.0082 3U4, McMaster University Medical Centre

🇨🇦

Hamilton, Ontario, Canada

502.373.0024 London HSC - University Hospital

🇨🇦

London, Ontario, Canada

502.373.0044 Mississauga Clinical Research Centre

🇨🇦

Mississauga, Ontario, Canada

502.373.0043 Fraser Clinical Trial Inc

🇨🇦

New Westminster, Ontario, Canada

502.373.0032 New Market Cardiology Research Grp

🇨🇦

Newmarket, Ontario, Canada

502.373.0037 Niagara Falls Medical Centre

🇨🇦

Niagara Falls, Ontario, Canada

502.373.0054 Orleans Medical-Dental Centre

🇨🇦

Orleans, Ontario, Canada

502.373.0029 Riverside Professional Building

🇨🇦

Ottawa, Ontario, Canada

502.373.0051 Merivale Cardiovascular Consultants

🇨🇦

Ottawa, Ontario, Canada

502.373.0063 Paradigm Clinical Trials

🇨🇦

Oshawa, Ontario, Canada

502.373.0040 Etobicok Cardiology

🇨🇦

Rexdale, Ontario, Canada

502.373.0039 Scarborough Cardiology Research

🇨🇦

Scarborough, Ontario, Canada

502.373.0061 CLIKS Medical Research Corp

🇨🇦

Thunder Bay, Ontario, Canada

502.373.0007 Sudbury Cardiac Research

🇨🇦

Sudbury, Ontario, Canada

502.373.0042 Sunnybrook & Woman's College Health Science Centre

🇨🇦

Toronto, Ontario, Canada

502.373.0008 Windsor Health Clinic

🇨🇦

Windsor, Ontario, Canada

502.373.0052 Dr. Bruce Lubelsky

🇨🇦

Willowdale, Ontario, Canada

502.373.0081 Centre de recherche clinique, CUSE 3001

🇨🇦

Fleurimont, Quebec, Canada

502.373.0076 Centre Hospitalier de Vallees de l'Outaouais Gatineau

🇨🇦

Gatineau, Quebec, Canada

502.373.0602 Boehringer Ingelheim Investigational Site

🇨🇳

Beijing, China

502.373.0010 Recherche Invascor

🇨🇦

Longueuil, Quebec, Canada

502.373.0086 Via Car Recherche Clinique Inc

🇨🇦

Longueuil, Quebec, Canada

502.373.0016 Suite 170

🇨🇦

Longueuil, Quebec, Canada

502.373.0018 Montreal Heart Institute

🇨🇦

Montreal, Quebec, Canada

502.373.0022 CHUM - Hotel Dieu

🇨🇦

Montreal, Quebec, Canada

502.373.0012 Hopital Laval - Institute Cardiologie de Quebec

🇨🇦

Ste-Foy, Quebec, Canada

502.373.0027 Ctr Hospitalier Beauce Etchemin

🇨🇦

St George de Beauce, Quebec, Canada

502.373.0026 Centre hospitalier Pierre-Le Gardeur

🇨🇦

Terrebonne, Quebec, Canada

502.373.0066 SDRI - University of Saskatchewan

🇨🇦

Saskatoon, Saskatchewan, Canada

502.373.0070 SDRI - University of Saskatchewan

🇨🇦

Saskatoon, Saskatchewan, Canada

502.373.0030 Portage Clinical Studies

🇨🇦

Manitoba, Canada

502.373.0028 Hop. Du St. Sacrement

🇨🇦

Quebec, Canada

502.373.0041 Recherches Clinicar Inc.

🇨🇦

Quebec, Canada

502.373.0080 Polyclinique vasculaire Centre hospitalier universitaire de

🇨🇦

Quebec, Canada

502.373.0601 Boehringer Ingelheim Investigational Site

🇨🇳

Beijing, China

502.373.0084 CHA-Hopital de l'Efant-Jesus

🇨🇦

Quebec, Canada

502.373.0603 Boehringer Ingelheim Investigational Site

🇨🇳

Beijing, China

502.373.0604 Boehringer Ingelheim Investigational Site

🇨🇳

Beijing, China

502.373.0623 Boehringer Ingelheim Investigational Site

🇨🇳

Beijing, China

502.373.0622 Boehringer Ingelheim Investigational Site

🇨🇳

Beijing, China

502.373.0606 Boehringer Ingelheim Investigational Site

🇨🇳

Beijing, China

502.373.0607 Boehringer Ingelheim Investigational Site

🇨🇳

Beijing, China

502.373.0621 Boehringer Ingelheim Investigational Site

🇨🇳

Beijing, China

502.373.0626 Boehringer Ingelheim Investigational Site

🇨🇳

Beijing, China

502.373.0616 Boehringer Ingelheim Investigational Site

🇨🇳

Changsha, China

502.373.0613 Boehringer Ingelheim Investigational Site

🇨🇳

Chengdu, China

502.373.0620 Boehringer Ingelheim Investigational Site

🇨🇳

Guangzhou, China

502.373.0634 Boehringer Ingelheim Investigational Site

🇨🇳

HeBei Province, China

502.373.0625 Boehringer Ingelheim Investigational Site

🇨🇳

Chengdu, China

502.373.0633 Boehringer Ingelheim Investigational Site

🇨🇳

ShanDong Province, China

502.373.0614 Boehringer Ingelheim Investigational Site

🇨🇳

Nanjing, China

502.373.0624 Boehringer Ingelheim Investigational Site

🇨🇳

Henan Province, China

502.373.0627 Boehringer Ingelheim Investigational Site

🇨🇳

Hubei Province, China

502.373.0619 Boehringer Ingelheim Investigational Site

🇨🇳

Shanghai, China

502.373.0629 Boehringer Ingelheim Investigational Site

🇨🇳

QingDao, China

502.373.0632 Boehringer Ingelheim Investigational Site

🇨🇳

ShanDong Province, China

502.373.0617 Boehringer Ingelheim Investigational Site

🇨🇳

Shanghai, China

502.373.0618 Boehringer Ingelheim Investigational Site

🇨🇳

Shanghai, China

502.373.0628 Boehringer Ingelheim Investigational Site

🇨🇳

Shen Yang, China

502.373.0611 Boehringer Ingelheim Investigational Site

🇨🇳

Shijiazhuang, China

502.373.0615 Boehringer Ingelheim Investigational Site

🇨🇳

Tianjin, China

502.373.0631 Boehringer Ingelheim Investigational Site

🇨🇳

Tianjin, China

502.373.0630 Boehringer Ingelheim Investigational Site

🇨🇳

Weizikeng, China

502.373.0608 Boehringer Ingelheim Investigational Site

🇨🇳

Wuhan, China

502.373.1055 Boehringer Ingelheim Investigational Site

🇨🇿

Kladno, Czech Republic

502.373.1053 Boehringer Ingelheim Investigational Site

🇨🇿

Brno, Czech Republic

502.373.1060 Boehringer Ingelheim Investigational Site

🇨🇿

Havirov, Czech Republic

502.373.1059 Boehringer Ingelheim Investigational Site

🇨🇿

Mlada Boleslav, Czech Republic

502.373.1061 Boehringer Ingelheim Investigational Site

🇨🇿

Plzen, Czech Republic

502.373.1056 Boehringer Ingelheim Investigational Site

🇨🇿

Pribram 1, Czech Republic

502.373.1058 Boehringer Ingelheim Investigational Site

🇨🇿

Usti nad Orlici, Czech Republic

502.373.1450 Boehringer Ingelheim Investigational Site

🇩🇰

Aalborg, Denmark

502.373.1453 Boehringer Ingelheim Investigational Site

🇩🇰

Aarhus C, Denmark

502.373.1459 Boehringer Ingelheim Investigational Site

🇩🇰

Frederiksberg C, Denmark

502.373.1460 Boehringer Ingelheim Investigational Site

🇩🇰

Helsingoer, Denmark

502.373.1452 Boehringer Ingelheim Investigational Site

🇩🇰

Hvidovre, Denmark

502.373.1451 Boehringer Ingelheim Investigational Site

🇩🇰

Holbaek, Denmark

502.373.1461 Boehringer Ingelheim Investigational Site

🇩🇰

Kjellerup, Denmark

502.373.1456 Boehringer Ingelheim Investigational Site

🇩🇰

Randers, Denmark

502.373.1470 Boehringer Ingelheim Investigational Site

🇫🇮

Helsinki, Finland

502.373.1473 Boehringer Ingelheim Investigational Site

🇫🇮

Helsinki, Finland

502.373.1487 Boehringer Ingelheim Investigational Site

🇫🇮

Liperi, Finland

502.373.1457 Boehringer Ingelheim Investigational Site

🇩🇰

Slagelse, Denmark

502.373.1454 Boehringer Ingelheim Investigational Site

🇩🇰

Svendborg, Denmark

502.373.1486 Boehringer Ingelheim Investigational Site

🇫🇮

Hämeenlinna, Finland

502.373.1475 Boehringer Ingelheim Investigational Site

🇫🇮

Oulun kaupunki, Finland

502.373.1479 Boehringer Ingelheim Investigational Site

🇫🇮

Jyväskylä, Finland

502.373.1488 Boehringer Ingelheim Investigational Site

🇫🇮

Kuopio, Finland

502.373.1090 Cabinet Médical

🇫🇷

Beziers, France

502.373.1485 Boehringer Ingelheim Investigational Site

🇫🇮

Vantaa, Finland

502.373.1075 Cabinet Médical

🇫🇷

Bourges, France

502.373.1093 Cabinet Médical

🇫🇷

Albens, France

502.373.1089 Cabinet Médical

🇫🇷

Gemenos, France

502.373.1099 Cabinet Médical

🇫🇷

Husseren Wesserlin, France

502.373.1094 Cabinet Médical

🇫🇷

Hyeres, France

502.373.1078 Cabinet Médical des Tanneurs

🇫🇷

L'Aigle, France

502.373.1083 Cabinet Médical

🇫🇷

Murs Erigne, France

502.373.1095 Cabinet Médical

🇫🇷

Ortez, France

502.373.1081 Cabinet Médical

🇫🇷

Le Pradet, France

502.373.1096 Cabinet Médical

🇫🇷

La Rochelle, France

502.373.1084 Cabinet Médical

🇫🇷

Nantes, France

502.373.1080 Cabinet Médical

🇫🇷

Niort, France

502.373.1079 Cabinet Médical

🇫🇷

Paris, France

502.373.1088 Cabinet Médical

🇫🇷

Rennes, France

502.373.1085 Cabinet Médical

🇫🇷

Saint Julien des Landes, France

502.373.1166 Boehringer Ingelheim Investigational Site

🇩🇪

Bad Lauterberg, Germany

502.373.1164 Boehringer Ingelheim Investigational Site

🇩🇪

Bad Lausick, Germany

502.373.1098 Cabinet Médical

🇫🇷

Rosiers d'Egletons, France

502.373.1087 Cabinet Médical

🇫🇷

Strasbourg, France

502.373.1092 Cabinet Médical de St Pierre

🇫🇷

Saint Pierre de Chandieu, France

502.373.1077 Cabinet Médical

🇫🇷

Saint Romain sur Cher, France

502.373.1076 Cabinet Médical La Grande Ramée

🇫🇷

Saint Martin dHyeres, France

502.373.1082 Cabinet Médical

🇫🇷

Tours, France

502.373.1138 Boehringer Ingelheim Investigational Site

🇩🇪

Bad Mergentheim, Germany

502.373.1156 Boehringer Ingelheim Investigational Site

🇩🇪

Berlin, Germany

502.373.1152 Boehringer Ingelheim Investigational Site

🇩🇪

Dessau, Germany

502.373.1160 Boehringer Ingelheim Investigational Site

🇩🇪

Berlin, Germany

502.373.1161 Boehringer Ingelheim Investigational Site

🇩🇪

Berlin, Germany

502.373.1144 Boehringer Ingelheim Investigational Site

🇩🇪

Bielefeld, Germany

502.373.1139 Boehringer Ingelheim Investigational Site

🇩🇪

Dortmund, Germany

502.373.1155 Boehringer Ingelheim Investigational Site

🇩🇪

Erlangen, Germany

502.373.1159 Boehringer Ingelheim Investigational Site

🇩🇪

Dortmund, Germany

502.373.1136 Boehringer Ingelheim Investigational Site

🇩🇪

Dresden, Germany

502.373.1145 Boehringer Ingelheim Investigational Site

🇩🇪

Eberswalde, Germany

502.373.1157 Boehringer Ingelheim Investigational Site

🇩🇪

Essen, Germany

502.373.1153 Boehringer Ingelheim Investigational Site

🇩🇪

Haag, Germany

502.373.1148 Boehringer Ingelheim Investigational Site

🇩🇪

Hamburg, Germany

502.373.1132 Boehringer Ingelheim Investigational Site

🇩🇪

Heidelberg, Germany

502.373.1131 Boehringer Ingelheim Investigational Site

🇩🇪

Homburg/Saar, Germany

502.373.1147 Boehringer Ingelheim Investigational Site

🇩🇪

Karlsburg, Germany

502.373.1154 Boehringer Ingelheim Investigational Site

🇩🇪

Kelkheim, Germany

502.373.1142 Boehringer Ingelheim Investigational Site

🇩🇪

Künzing, Germany

502.373.1137 Boehringer Ingelheim Investigational Site

🇩🇪

Köln, Germany

502.373.1165 Boehringer Ingelheim Investigational Site

🇩🇪

Lübeck, Germany

502.373.1134 Boehringer Ingelheim Investigational Site

🇩🇪

Mainz, Germany

502.373.1133 Boehringer Ingelheim Investigational Site

🇩🇪

Melsungen, Germany

502.373.1146 Boehringer Ingelheim Investigational Site

🇩🇪

München, Germany

502.373.1149 Boehringer Ingelheim Investigational Site

🇩🇪

Offenbach am Main, Germany

502.373.1162 Boehringer Ingelheim Investigational Site

🇩🇪

Riesa, Germany

502.373.1163 Boehringer Ingelheim Investigational Site

🇩🇪

Starnberg, Germany

502.373.1135 Boehringer Ingelheim Investigational Site

🇩🇪

Wiesbaden, Germany

502.373.1141 Boehringer Ingelheim Investigational Site

🇩🇪

Witten, Germany

502.373.1200 Boehringer Ingelheim Investigational Site

🇬🇷

Athens, Greece

502.373.1207 Boehringer Ingelheim Investigational Site

🇬🇷

Athens, Greece

502.373.1203 Boehringer Ingelheim Investigational Site

🇬🇷

Athens, Greece

502.373.1208 Boehringer Ingelheim Investigational Site

🇬🇷

Athens, Greece

502.373.1206 Boehringer Ingelheim Investigational Site

🇬🇷

Athens, Greece

502.373.1214 Boehringer Ingelheim Investigational Site

🇬🇷

Athens, Greece

502.373.1211 Boehringer Ingelheim Investigational Site

🇬🇷

Goudi/ Athens, Greece

502.373.1209 Boehringer Ingelheim Investigational Site

🇬🇷

Elefsina, Greece

502.373.1202 Boehringer Ingelheim Investigational Site

🇬🇷

Melissia, Athens, Greece

502.373.1201 Boehringer Ingelheim Investigational Site

🇬🇷

Ioannina, Greece

502.373.0676 Boehringer Ingelheim Investigational Site

🇭🇰

Hong Kong, Hong Kong

502.373.0677 Boehringer Ingelheim Investigational Site

🇭🇰

Hong Kong, Hong Kong

502.373.1204 Boehringer Ingelheim Investigational Site

🇬🇷

Veria, Greece

502.373.0681 Boehringer Ingelheim Investigational Site

🇭🇰

Hong Kong, Hong Kong

502.373.0685 Boehringer Ingelheim Investigational Site

🇭🇰

Hong Kong, Hong Kong

502.373.1231 Boehringer Ingelheim Investigational Site

🇭🇺

Budapest, Hungary

502.373.1230 Boehringer Ingelheim Investigational Site

🇭🇺

Budapest, Hungary

502.373.1232 Boehringer Ingelheim Investigational Site

🇭🇺

Budapest, Hungary

502.373.1233 Boehringer Ingelheim Investigational Site

🇭🇺

Budapest, Hungary

502.373.1235 Boehringer Ingelheim Investigational Site

🇭🇺

Budapest, Hungary

502.373.1237 Boehringer Ingelheim Investigational Site

🇭🇺

Budapest, Hungary

502.373.1239 Boehringer Ingelheim Investigational Site

🇭🇺

Budapest, Hungary

502.373.1234 Boehringer Ingelheim Investigational Site

🇭🇺

Tatabanya, Hungary

502.373.1242 Boehringer Ingelheim Investigational Site

🇭🇺

Budapest, Hungary

502.373.1244 Boehringer Ingelheim Investigational Site

🇭🇺

Budapest, Hungary

502.373.1236 Boehringer Ingelheim Investigational Site

🇭🇺

Debrecen, Hungary

502.373.1240 Boehringer Ingelheim Investigational Site

🇭🇺

Debrecen, Hungary

502.373.1228 Boehringer Ingelheim Investigational Site

🇭🇺

Kecskemet, Hungary

502.373.1241 Boehringer Ingelheim Investigational Site

🇭🇺

Nyiregyhaza, Hungary

502.373.1238 Boehringer Ingelheim Investigational Site

🇭🇺

Szeged, Hungary

502.373.1229 Boehringer Ingelheim Investigational Site

🇭🇺

Siofok, Hungary

502.373.1226 Boehringer Ingelheim Investigational Site

🇭🇺

Pecs, Hungary

502.373.1225 Boehringer Ingelheim Investigational Site

🇭🇺

Szekesfehervar, Hungary

502.373.1243 Boehringer Ingelheim Investigational Site

🇭🇺

Veszprem, Hungary

502.373.1717 Adelaide & Meath Hospitals

🇮🇪

Dublin 24, Ireland

502.373.1714 Dept. of Clinical Pharmacology

🇮🇪

Dublin 8, Ireland

502.373.1719 Pulmonary Function Laboratory

🇮🇪

Dublin 9, Ireland

502.373.1720 Mallow General Hospital

🇮🇪

Mallow, Ireland

502.373.1259 Ospedale di Bentivoglio

🇮🇹

Bentivoglio (BO), Italy

502.373.1278 Ospedale Bellaria

🇮🇹

Bologna, Italy

502.373.1257 Ospedale "Mazzoni"

🇮🇹

Ascoli Piceno, Italy

502.373.1255 Ospedale "S. Orsola Malpighi"

🇮🇹

Bologna, Italy

502.373.1275 A.O. Spedali Civili di Brescia -Univ. degli studi di Brescia

🇮🇹

Brescia, Italy

502.373.1252 Azienda Ospedaliera di Caserta

🇮🇹

Caserta, Italy

502.373.1254 Ospedale di Città della Pieve

🇮🇹

Città della Pieve (PG), Italy

502.373.1262 Arcispedale "S. Anna"

🇮🇹

Ferrara, Italy

502.373.1250 Ospedale Civile "S. Polo"

🇮🇹

Monfalcone (go), Italy

502.373.1267 Azienda Universitaria Policlinico II

🇮🇹

Napoli, Italy

502.373.1266 Azienda Universitaria Policlinico "Federico II"

🇮🇹

Napoli, Italy

502.373.1269 Università Federico II

🇮🇹

Napoli, Italy

502.373.1279 Asl Na 1

🇮🇹

Napoli, Italy

502.373.1251 Policlinico Monteluce

🇮🇹

Perugia, Italy

502.373.1253 Istituto di Ricovero a Carattere Scientifico Neuromed- IRCCS

🇮🇹

Pozzilli (IS), Italy

502.373.1264 Presidio Ospedaliero "Villa Sofia"

🇮🇹

Palermo, Italy

502.373.1265 IRCCS - Policlinico S. Matteo

🇮🇹

Pavia, Italy

502.373.1258 Ospedale "R. Silvestrini"

🇮🇹

Perugia, Italy

502.373.1274 Ospedale "R. Silvestrini"

🇮🇹

Perugia, Italy

502.373.1268 Ospedale "S. Spirito"

🇮🇹

Roma, Italy

502.373.1260 Ospedale "N. Melli"

🇮🇹

S. Pietro Vernotico (BR), Italy

502.373.1263 Policlinico Umberto I

🇮🇹

Roma, Italy

502.373.1270 Policlinico di Tor Vergata

🇮🇹

Roma, Italy

502.373.1273 A.O. "S. Camillo de Lellis"

🇮🇹

Roma, Italy

502.373.1256 Ospedale Civile SS. Annunziata - USL 1

🇮🇹

Sassari, Italy

502.373.1277 A.S.O. "S. Giovanni Battista"

🇮🇹

Torino, Italy

502.373.1272 Ospedale di Circolo di Varese

🇮🇹

Varese, Italy

502.373.1276 Ospedale Belcolle

🇮🇹

Viterbo, Italy

502.373.1271 Ospedale Civile

🇮🇹

Venezia, Italy

502.373.0763 Boehringer Ingelheim Investigational Site

🇰🇷

Incheon, Korea, Republic of

502.373.0755 Boehringer Ingelheim Investigational Site

🇰🇷

Pusan, Korea, Republic of

502.373.0764 Boehringer Ingelheim Investigational Site

🇰🇷

Kwang-ju, Korea, Republic of

502.373.0756 Boehringer Ingelheim Investigational Site

🇰🇷

Seoul, Korea, Republic of

502.373.0753 Boehringer Ingelheim Investigational Site

🇰🇷

Seoul, Korea, Republic of

502.373.0757 Boehringer Ingelheim Investigational Site

🇰🇷

Seoul, Korea, Republic of

502.373.2707 Boehringer Ingelheim Investigational Site

🇲🇾

Kelantan Darul Naim, Malaysia

502.373.0754 Boehringer Ingelheim Investigational Site

🇰🇷

Taegu, Korea, Republic of

502.373.0731 Boehringer Ingelheim Investigational Site

🇲🇾

Putrajaya, Malaysia

502.373.0733 Boehringer Ingelheim Investigational Site

🇲🇾

Penang, Malaysia

502.373.0732 Boehringer Ingelheim Investigational Site

🇲🇾

Kuala Lumpur, Malaysia

502.373.0734 Boehringer Ingelheim Investigational Site

🇲🇾

Kuala Lumpur, Malaysia

502.373.60001 Boehringer Ingelheim Investigational Site

🇲🇾

Selangor, Malaysia

502.373.0451 Boehringer Ingelheim Investigational Site

🇲🇽

Guadalajara, Mexico

502.373.0459 Boehringer Ingelheim Investigational Site

🇲🇽

Guadalajara, Mexico

502.373.0450 Boehringer Ingelheim Investigational Site

🇲🇽

Guadalajara, Mexico

502.373.0452 Boehringer Ingelheim Investigational Site

🇲🇽

Guadalajara, Mexico

502.373.0460 Boehringer Ingelheim Investigational Site

🇲🇽

Guadalajara, Mexico

502.373.0470 Boehringer Ingelheim Investigational Site

🇲🇽

Guadalajara, Mexico

502.373.0461 Boehringer Ingelheim Investigational Site

🇲🇽

Guadalajara, Mexico

502.373.0457 Boehringer Ingelheim Investigational Site

🇲🇽

Mexico, Mexico

502.373.0458 Boehringer Ingelheim Investigational Site

🇲🇽

Mexico, Mexico

502.373.0453 Boehringer Ingelheim Investigational Site

🇲🇽

Zapopan, Mexico

502.373.1309 Boehringer Ingelheim Investigational Site

🇳🇱

Amsterdam, Netherlands

502.373.0454 Boehringer Ingelheim Investigational Site

🇲🇽

Monterrey, Mexico

502.373.1305 Boehringer Ingelheim Investigational Site

🇳🇱

Beverwijk, Netherlands

502.373.0456 Boehringer Ingelheim Investigational Site

🇲🇽

Zapopan, Mexico

502.373.1313 Boehringer Ingelheim Investigational Site

🇳🇱

Den Bosch, Netherlands

502.373.1312 Boehringer Ingelheim Investigational Site

🇳🇱

Den Haag, Netherlands

502.373.1301 Boehringer Ingelheim Investigational Site

🇳🇱

Eindhoven, Netherlands

502.373.1318 Boehringer Ingelheim Investigational Site

🇳🇱

Ermelo, Netherlands

502.373.1310 Boehringer Ingelheim Investigational Site

🇳🇱

Hengelo, Netherlands

502.373.1320 Boehringer Ingelheim Investigational Site

🇳🇱

Ewijk, Netherlands

502.373.1303 Boehringer Ingelheim Investigational Site

🇳🇱

Hoorn, Netherlands

502.373.1300 Boehringer Ingelheim Investigational Site

🇳🇱

Lichtenvoorde, Netherlands

502.373.1322 Boehringer Ingelheim Investigational Site

🇳🇱

Huizen, Netherlands

502.373.1317 Boehringer Ingelheim Investigational Site

🇳🇱

Rijswijk, Netherlands

502.373.1323 Boehringer Ingelheim Investigational Site

🇳🇱

Losser, Netherlands

502.373.1307 Boehringer Ingelheim Investigational Site

🇳🇱

Nieuwegein, Netherlands

502.373.1319 Boehringer Ingelheim Investigational Site

🇳🇱

Roelofarendsveen, Netherlands

502.373.1308 Boehringer Ingelheim Investigational Site

🇳🇱

Rotterdam, Netherlands

502.373.1316 Boehringer Ingelheim Investigational Site

🇳🇱

Utrecht, Netherlands

502.373.0502 Boehringer Ingelheim Investigational Site

🇳🇿

Auckland 3, New Zealand

502.373.1321 Boehringer Ingelheim Investigational Site

🇳🇱

Spijkenisse, Netherlands

502.373.1314 Boehringer Ingelheim Investigational Site

🇳🇱

Tilburg, Netherlands

502.373.0500 Boehringer Ingelheim Investigational Site

🇳🇿

Auckland, New Zealand

502.373.1311 Boehringer Ingelheim Investigational Site

🇳🇱

Stadskanaal, Netherlands

502.373.0507 Boehringer Ingelheim Investigational Site

🇳🇿

Christchurch, New Zealand

502.373.1315 Boehringer Ingelheim Investigational Site

🇳🇱

Velp, Netherlands

502.373.0506 Boehringer Ingelheim Investigational Site

🇳🇿

Hasting, New Zealand

502.373.0504 Boehringer Ingelheim Investigational Site

🇳🇿

Hamiton, New Zealand

502.373.0501 Middlemore Hospital

🇳🇿

Otahuhu Auckland, New Zealand

502.373.0503 Boehringer Ingelheim Investigational Site

🇳🇿

Takapuna Auckland, New Zealand

502.373.0505 Tauranga Study Centre

🇳🇿

Tauranga, New Zealand

502.373.20003 Boehringer Ingelheim Investigational Site

🇳🇴

Fevik, Norway

502.373.20001 Stavanger Universitetssykehus

🇳🇴

Stavanger, Norway

502.373.20004 Fana Hjertesenter

🇳🇴

Nesttun, Norway

502.373.20002 Tvedestrand Legesenter

🇳🇴

Tvedestrand, Norway

502.373.20005 Sykehuset i Vestfold, Avd. Tønsberg

🇳🇴

Tønsberg, Norway

502.373.0703 Philippine Heart Center

🇵🇭

Quezon City, Philippines

502.373.0704 National Kidney & Transplant Institute, Room 821

🇵🇭

Quezon City, Philippines

502.373.1354 Boehringer Ingelheim Investigational Site

🇵🇱

Bydgoszcz, Poland

502.373.1368 Boehringer Ingelheim Investigational Site

🇵🇱

Gdynia, Poland

502.373.1365 Boehringer Ingelheim Investigational Site

🇵🇱

Gdynia Redlowo, Poland

502.373.1359 Boehringer Ingelheim Investigational Site

🇵🇱

Grojec, Poland

502.373.1369 Boehringer Ingelheim Investigational Site

🇵🇱

Grudziadz, Poland

502.373.1375 Boehringer Ingelheim Investigational Site

🇵🇱

Inowroclaw, Poland

502.373.1372 Boehringer Ingelheim Investigational Site

🇵🇱

Katowice, Poland

502.373.1376 Boehringer Ingelheim Investigational Site

🇵🇱

Katowice, Poland

502.373.1361 Boehringer Ingelheim Investigational Site

🇵🇱

Kielce, Poland

502.373.1358 Boehringer Ingelheim Investigational Site

🇵🇱

Lodz, Poland

502.373.1364 Boehringer Ingelheim Investigational Site

🇵🇱

Lubartow, Poland

502.373.1367 Boehringer Ingelheim Investigational Site

🇵🇱

Nowy Sacz, Poland

502.373.1374 Boehringer Ingelheim Investigational Site

🇵🇱

Lubin, Poland

502.373.1356 Boehringer Ingelheim Investigational Site

🇵🇱

Piotrkow Trybunalski, Poland

502.373.1352 Boehringer Ingelheim Investigational Site

🇵🇱

Skierniewice, Poland

502.373.1357 Boehringer Ingelheim Investigational Site

🇵🇱

Ruda Slaska, Poland

502.373.1362 Boehringer Ingelheim Investigational Site

🇵🇱

Tarnow, Poland

502.373.1351 Boehringer Ingelheim Investigational Site

🇵🇱

Warsaw, Poland

502.373.1353 Boehringer Ingelheim Investigational Site

🇵🇱

Torun, Poland

502.373.1402 Hospital Garcia de Orta

🇵🇹

Almada, Portugal

502.373.1363 Boehringer Ingelheim Investigational Site

🇵🇱

Warsaw, Poland

502.373.1373 Boehringer Ingelheim Investigational Site

🇵🇱

Wegrow, Poland

502.373.1400 Hospital Fernando Fonseca

🇵🇹

Amadora, Portugal

502.373.1411 Hospital de Santa Cruz

🇵🇹

Carnaxide, Portugal

502.373.1406 Hospital Distrital de Faro Geral

🇵🇹

Faro, Portugal

502.373.1408 Hospitais da Universidade de Coimbra

🇵🇹

Coimbra, Portugal

502.373.1403 Hospital de Santa Marta

🇵🇹

Lisboa, Portugal

502.373.1409 Hospital de Santa Maria

🇵🇹

Lisboa, Portugal

502.373.1401 Unidade Local de Saúde de Matosinhos

🇵🇹

Matosinhos, Portugal

502.373.0215 Boehringer Ingelheim Investigational Site

🇵🇷

Caguas, Puerto Rico

502.373.1407 Centro Hospitalar vila Nova de Gaia

🇵🇹

Vila Nova de Gaia, Portugal

502.373.1410 Hospital de Santo António

🇵🇹

Porto, Portugal

502.373.0198 Boehringer Ingelheim Investigational Site

🇵🇷

Orocovis, Puerto Rico

502.373.0262 Boehringer Ingelheim Investigational Site

🇵🇷

Rio Piedras, Puerto Rico

502.373.1426 Boehringer Ingelheim Investigational Site

🇷🇺

Moscow, Russian Federation

502.373.1427 Boehringer Ingelheim Investigational Site

🇷🇺

Moscow, Russian Federation

502.373.1425 Boehringer Ingelheim Investigational Site

🇷🇺

Moscow, Russian Federation

502.373.1428 Boehringer Ingelheim Investigational Site

🇷🇺

Moscow, Russian Federation

502.373.1429 Boehringer Ingelheim Investigational Site

🇷🇺

Moscow, Russian Federation

502.373.1433 Boehringer Ingelheim Investigational Site

🇷🇺

Moscow, Russian Federation

502.373.1430 Boehringer Ingelheim Investigational Site

🇷🇺

Moscow, Russian Federation

502.373.1431 Boehringer Ingelheim Investigational Site

🇷🇺

St. Petersburg, Russian Federation

502.373.1535 Boehringer Ingelheim Investigational Site

🇸🇰

Bratislava, Slovakia

502.373.1432 Boehringer Ingelheim Investigational Site

🇷🇺

St. Petersburg, Russian Federation

502.373.0726 Boehringer Ingelheim Investigational Site

🇸🇬

Singapore, Singapore

502.373.0725 Boehringer Ingelheim Investigational Site

🇸🇬

Singapore, Singapore

502.373.2706 Boehringer Ingelheim Investigational Site

🇸🇬

Kuala Lumpur, Singapore

502.373.1552 Boehringer Ingelheim Investigational Site

🇿🇦

Bloemfontein, South Africa

502.373.1529 Boehringer Ingelheim Investigational Site

🇸🇰

Kosice, Slovakia

502.373.1540 Boehringer Ingelheim Investigational Site

🇸🇰

Kosice, Slovakia

502.373.1545 Boehringer Ingelheim Investigational Site

🇸🇰

Rimavska Sobota, Slovakia

502.373.1538 Boehringer Ingelheim Investigational Site

🇸🇰

Nitra, Slovakia

502.373.1553 Boehringer Ingelheim Investigational Site

🇿🇦

Bellville, South Africa

502.373.1550 Boehringer Ingelheim Investigational Site

🇿🇦

Cape Town, South Africa

502.373.1554 Boehringer Ingelheim Investigational Site

🇿🇦

Congella, South Africa

502.373.1551 Boehringer Ingelheim Investigational Site

🇿🇦

Durban, South Africa

502.373.1561 Boehringer Ingelheim Investigational Site

🇿🇦

Cape Town, South Africa

502.373.1563 Boehringer Ingelheim Investigational Site

🇿🇦

George East, South Africa

502.373.1559 Boehringer Ingelheim Investigational Site

🇿🇦

Port Elizabeth, South Africa

502.373.1558 Boehringer Ingelheim Investigational Site

🇿🇦

Soweto, South Africa

502.373.1557 Boehringer Ingelheim Investigational Site

🇿🇦

Sunninghill, South Africa

502.373.1564 Boehringer Ingelheim Investigational Site

🇿🇦

Sunninghill, South Africa

502.373.1562 Boehringer Ingelheim Investigational Site

🇿🇦

Port Elizabeth, South Africa

502.373.1597 Boehringer Ingelheim Investigational Site

🇪🇸

Barcelona, Spain

502.373.1586 Boehringer Ingelheim Investigational Site

🇪🇸

Barcelona, Spain

502.373.1556 Boehringer Ingelheim Investigational Site

🇿🇦

Vanderbijlpark, South Africa

502.373.1582 Boehringer Ingelheim Investigational Site

🇪🇸

Alcorcón (Madrid), Spain

502.373.1599 Boehringer Ingelheim Investigational Site

🇪🇸

Barcelona, Spain

502.373.1595 Boehringer Ingelheim Investigational Site

🇪🇸

Burjasot (Valencia), Spain

502.373.1576 Boehringer Ingelheim Investigational Site

🇪🇸

Madrid, Spain

502.373.1584 Boehringer Ingelheim Investigational Site

🇪🇸

Granada, Spain

502.373.1585 Boehringer Ingelheim Investigational Site

🇪🇸

Granada, Spain

502.373.1578 Boehringer Ingelheim Investigational Site

🇪🇸

Madrid, Spain

502.373.1580 Boehringer Ingelheim Investigational Site

🇪🇸

Madrid, Spain

502.373.1594 Boehringer Ingelheim Investigational Site

🇪🇸

Murcia, Spain

502.373.1593 Boehringer Ingelheim Investigational Site

🇪🇸

Santiago de Compostela, Spain

502.373.1579 Boehringer Ingelheim Investigational Site

🇪🇸

Santiago de Compostela, Spain

502.373.1592 Boehringer Ingelheim Investigational Site

🇪🇸

Madrid, Spain

502.373.1596 Boehringer Ingelheim Investigational Site

🇪🇸

Málaga, Spain

502.373.1575 Boehringer Ingelheim Investigational Site

🇪🇸

Valencia, Spain

502.373.1598 Boehringer Ingelheim Investigational Site

🇪🇸

Santiago de Compostela, Spain

502.373.1583 Boehringer Ingelheim Investigational Site

🇪🇸

Sevilla, Spain

502.373.1504 Capio Lundby sjukhus

🇸🇪

Göteborg, Sweden

502.373.1501 Hjaertmottagningen

🇸🇪

Helsingborg, Sweden

502.373.1591 Boehringer Ingelheim Investigational Site

🇪🇸

Valencia, Spain

502.373.1514 Hjärt/Kärlforskn.enheten

🇸🇪

Göteborg, Sweden

502.373.1509 Hjärtsektionen / Med.kliniken

🇸🇪

Göteborg, Sweden

502.373.1502 Borgmästargaardens Läkarmottagning

🇸🇪

Malmoe, Sweden

502.373.1506 Hjärtmottagningen

🇸🇪

Malmö, Sweden

502.373.1507 Kardiologiska kliniken

🇸🇪

Malmö, Sweden

502.373.1508 Kolgahuset Läkargrupp

🇸🇪

Malmö, Sweden

502.373.1511 Sjuntorps Vaardcentral

🇸🇪

Sjuntorp, Sweden

502.373.1512 Vännäs Vaardcentral

🇸🇪

Vännäs, Sweden

502.373.1632 Boehringer Ingelheim Investigational Site

🇨🇭

Bellinzona, Switzerland

502.373.1634 Boehringer Ingelheim Investigational Site

🇨🇭

Bern, Switzerland

502.373.1625 Boehringer Ingelheim Investigational Site

🇨🇭

Basel, Switzerland

502.373.1503 Källtorps Vaardcentral

🇸🇪

Trollhättan, Sweden

502.373.1627 Boehringer Ingelheim Investigational Site

🇨🇭

Biel/Bienne, Switzerland

502.373.1633 Boehringer Ingelheim Investigational Site

🇨🇭

Kreuzlingen, Switzerland

502.373.1631 Boehringer Ingelheim Investigational Site

🇨🇭

Chur, Switzerland

502.373.1629 Boehringer Ingelheim Investigational Site

🇨🇭

Lugano, Switzerland

502.373.1637 Boehringer Ingelheim Investigational Site

🇨🇭

Zürich, Switzerland

502.373.0780 Boehringer Ingelheim Investigational Site

🇨🇳

Changhua, Taiwan

502.373.1628 Boehringer Ingelheim Investigational Site

🇨🇭

St. Gallen, Switzerland

502.373.0783 Boehringer Ingelheim Investigational Site

🇨🇳

Hualien, Taiwan

502.373.0778 Boehringer Ingelheim Investigational Site

🇨🇳

Kaohsiung, Taiwan

502.373.0776 Boehringer Ingelheim Investigational Site

🇨🇳

Kaohsiung, Taiwan

502.373.0781 Boehringer Ingelheim Investigational Site

🇨🇳

Taipei, Taiwan

502.373.0775 Boehringer Ingelheim Investigational Site

🇨🇳

Tainan, Taiwan

502.373.0804 Boehringer Ingelheim Investigational Site

🇹🇭

Bangkok, Thailand

502.373.0777 Boehringer Ingelheim Investigational Site

🇨🇳

Tainan, Taiwan

502.373.0782 Boehringer Ingelheim Investigational Site

🇨🇳

Taipei, Taiwan

502.373.0801 Boehringer Ingelheim Investigational Site

🇹🇭

Bangkok, Thailand

502.373.0802 Boehringer Ingelheim Investigational Site

🇹🇭

Bangkok, Thailand

502.373.0805 Boehringer Ingelheim Investigational Site

🇹🇭

Bangkok, Thailand

502.373.0806 Boehringer Ingelheim Investigational Site

🇹🇭

Bangkok, Thailand

502.373.0808 Boehringer Ingelheim Investigational Site

🇹🇭

Bangkok, Thailand

502.373.0807 Boehringer Ingelheim Investigational Site

🇹🇭

Nonthaburi, Thailand

502.373.1652 Cukurova Universitesi Tip Fakultesi

🇹🇷

Adana, Turkey

502.373.1651 Cukurova Universitesi Tip Fakultesi

🇹🇷

Adana, Turkey

502.373.1653 Ankara Hastanesi Endokrinoloji Bölümü

🇹🇷

Ankara, Turkey

502.373.1656 Baskent Universitesi Tip Fakultesi

🇹🇷

Ankara, Turkey

502.373.1659 Ankara Universitesi Tip Fakultesi

🇹🇷

Ankara, Turkey

502.373.1654 Göztepe SSK Egitim ve Arastirma Hastanesi

🇹🇷

Istanbul, Turkey

502.373.1655 Cerrahpasa Universitesi Tip Fakultesi

🇹🇷

Istanbul, Turkey

502.373.1658 Ege Universitesi Tip Fakultesi

🇹🇷

Izmir, Turkey

502.373.1731 Boehringer Ingelheim Investigational Site

🇺🇦

Dnyepropetrovsk, Ukraine

502.373.1730 Boehringer Ingelheim Investigational Site

🇺🇦

Dnyepropetrovsk, Ukraine

502.373.1657 Haseki Hastanesi

🇹🇷

Istanbul, Turkey

502.373.1650 Erciyes Universitesi Tip Fakultesi Kardiyoloji Anabilim Dali

🇹🇷

Kayseri, Turkey

502.373.1728 Boehringer Ingelheim Investigational Site

🇺🇦

Kharkov, Ukraine

502.373.1725 Boehringer Ingelheim Investigational Site

🇺🇦

Kiev, Ukraine

502.373.1733 Boehringer Ingelheim Investigational Site

🇺🇦

Kharkov, Ukraine

502.373.1732 Boehringer Ingelheim Investigational Site

🇺🇦

Kharkov, Ukraine

502.373.1726 Boehringer Ingelheim Investigational Site

🇺🇦

Kiev, Ukraine

502.373.1727 Boehringer Ingelheim Investigational Site

🇺🇦

Kiev, Ukraine

502.373.1729 Boehringer Ingelheim Investigational Site

🇺🇦

Kiev, Ukraine

502.373.1734 Boehringer Ingelheim Investigational Site

🇺🇦

Kiev, Ukraine

502.373.1675 Boehringer Ingelheim Investigational Site

🇦🇪

Dubai, United Arab Emirates

502.373.1680 Boehringer Ingelheim Investigational Site

🇦🇪

Abu Dhabi, United Arab Emirates

502.373.1677 Boehringer Ingelheim Investigational Site

🇦🇪

Sharjah, United Arab Emirates

502.373.1679 Boehringer Ingelheim Investigational Site

🇦🇪

Dubai, United Arab Emirates

502.373.1698 Boehringer Ingelheim Investigational Site

🇬🇧

Aberdeen, United Kingdom

502.373.1694 Boehringer Ingelheim Investigational Site

🇬🇧

Birmingham, United Kingdom

502.373.1706 Boehringer Ingelheim Investigational Site

🇬🇧

Bathampton, United Kingdom

502.373.1690 Boehringer Ingelheim Investigational Site

🇬🇧

Belfast, United Kingdom

502.373.1707 Boehringer Ingelheim Investigational Site

🇬🇧

Brighton, United Kingdom

502.373.1703 Boehringer Ingelheim Investigational Site

🇬🇧

Cardiff, United Kingdom

502.373.1709 Boehringer Ingelheim Investigational Site

🇬🇧

Chichester, United Kingdom

502.373.1701 Boehringer Ingelheim Investigational Site

🇬🇧

Derby, United Kingdom

502.373.1700 Boehringer Ingelheim Investigational Site

🇬🇧

Kirkcaldy, Fife, United Kingdom

502.373.1705 Boehringer Ingelheim Investigational Site

🇬🇧

Gateshead, United Kingdom

502.373.1710 Boehringer Ingelheim Investigational Site

🇬🇧

Glasgow, United Kingdom

502.373.1691 Boehringer Ingelheim Investigational Site

🇬🇧

Leeds, United Kingdom

502.373.1699 Boehringer Ingelheim Investigational Site

🇬🇧

Leicester, United Kingdom

502.373.1702 Boehringer Ingelheim Investigational Site

🇬🇧

Lincoln, United Kingdom

502.373.1697 Boehringer Ingelheim Investigational Site

🇬🇧

Liverpool, United Kingdom

502.373.1693 Boehringer Ingelheim Investigational Site

🇬🇧

Manchester, United Kingdom

502.373.1708 Boehringer Ingelheim Investigational Site

🇬🇧

Portadown, County Atrim, United Kingdom

502.373.1695 Boehringer Ingelheim Investigational Site

🇬🇧

London, United Kingdom

502.373.1696 Boehringer Ingelheim Investigational Site

🇬🇧

Sheffield, United Kingdom

502.373.1704 Boehringer Ingelheim Investigational Site

🇬🇧

Stirling, United Kingdom

502.373.1692 Boehringer Ingelheim Investigational Site

🇬🇧

Rugby, United Kingdom

502.373.0750 Boehringer Ingelheim Investigational Site

🇰🇷

Seoul, Korea, Republic of

502.373.1589 Boehringer Ingelheim Investigational Site

🇪🇸

Madrid, Spain

502.373.0161 Boehringer Ingelheim Investigational Site

🇺🇸

Augusta, Georgia, United States

502.373.0193 Boehringer Ingelheim Investigational Site

🇺🇸

Augusta, Georgia, United States

502.373.0245 Boehringer Ingelheim Investigational Site

🇺🇸

Savannah, Georgia, United States

502.373.0158 Boehringer Ingelheim Investigational Site

🇺🇸

Shreveport, Louisiana, United States

502.373.0760 Boehringer Ingelheim Investigational Site

🇰🇷

Seoul, Korea, Republic of

502.373.0221 Boehringer Ingelheim Investigational Site

🇺🇸

Fort Worth, Texas, United States

502.373.0239 Boehringer Ingelheim Investigational Site

🇺🇸

St. Louis, Missouri, United States

502.373.0077 Health Science Centre Diabetes Research Group

🇨🇦

Winnipeg, Manitoba, Canada

502.373.0045 Queen Elizabeth II HSC

🇨🇦

Halifax, Nova Scotia, Canada

502.373.0270 Boehringer Ingelheim Investigational Site

🇺🇸

Des Moines, Iowa, United States

502.373.0150 Boehringer Ingelheim Investigational Site

🇺🇸

Bronx, New York, United States

502.373.0175 Boehringer Ingelheim Investigational Site

🇺🇸

Sacramento, California, United States

502.373.0179 Boehringer Ingelheim Investigational Site

🇺🇸

Gainesville, Florida, United States

502.373.0195 Boehringer Ingelheim Investigational Site

🇺🇸

Kansas City, Missouri, United States

502.373.0156 Boehringer Ingelheim Investigational Site

🇺🇸

Rochester, New York, United States

502.373.0264 Boehringer Ingelheim Investigational Site

🇺🇸

Rochester, New York, United States

502.373.0168 Boehringer Ingelheim Investigational Site

🇺🇸

Dayton, Ohio, United States

502.373.0184 Boehringer Ingelheim Investigational Site

🇺🇸

Charleston, South Carolina, United States

502.373.0020 CHA/University Hospital

🇨🇦

Edmonton, Alberta, Canada

502.373.0680 Boehringer Ingelheim Investigational Site

🇭🇰

Hong Kong, Hong Kong

Related Trials

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy